

**DESCRIPTION**


<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse IL-17F in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant mouse (rm) IL-17, rmIL-17B, C, D, E, or recombinant human IL-17F is observed.
<b>Source</b>	Monoclonal Rat IgG <sub>2A</sub> Clone # 316016
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant mouse IL-17F Arg29-Ala161 Accession # Q7TNI7
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	1 µg/mL	Recombinant Mouse IL-17F (Catalog # 2057-IL)
<b>Intracellular Staining by Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

The Interleukin 17 (IL-17) family proteins, comprised of six members (IL-17, IL-17B through IL-17F), are secreted, structurally related proteins that share a conserved cysteine-knot fold near the C-terminus, but have considerable sequence divergence at the N-terminus. With the exception of IL-17B, which exists as a non-covalently linked dimer, all IL-17 family members are disulfide-linked dimers. IL-17 family proteins are pro-inflammatory cytokines that induce local cytokine production and are involved in the regulation of immune functions (1, 2).

Mouse IL-17F cDNA encodes a 153 amino acid (aa) protein with a putative 20 aa signal peptide. Among IL-17 family members, IL-17F is most closely related to IL-17 sharing approximately 46% aa sequence identity. Mouse and human IL-17F share 55% sequence identity. IL-17F is expressed in activated CD4<sup>+</sup> T cells and activated monocytes. Two receptors (IL-17 R, and IL-17B R), which are activated by IL-17 family members have been identified. In addition, at least three additional type I transmembrane receptors with homology to IL-17 R, including IL-17 RL (IL-17 RC), IL-17 RD, and IL-17 RE, have also been reported (1, 2, 5). The functions for IL-17 RC, D, and E are not known. Purified IL-17 R and IL-17B R do not bind IL-17F with high-affinity *in vitro*. However, binding of IL-17F is detected in cells transfected with IL-17 R, raising the possibility that a co-receptor may be required for IL-17F signaling through IL-17 R (4). The biological activities mediated by IL-17F are similar to those of IL-17. IL-17F stimulates production of IL-6, IL-8, G-CSF, and regulates cartilage matrix turnover by increasing matrix release and inhibiting new matrix synthesis (4). IL-17F also inhibits angiogenesis and induces production of IL-2, TGF- $\beta$ , and monocyte chemoattractant protein-1 in endothelial cells (3).

**References:**

1. Aggarwal, S. and A.L. Gurney (2002) *J. Leukoc. Biol.* **71**:1.
2. Moseley, T.A. *et al.* (2003) *Cytokine & Growth Factor Rev.* **14**:155.
3. Starnes, T. *et al.* (2001) *J. Immunol.* **167**:4137.
4. Hurst, S.D. *et al.* (2002) *J. Immunol.* **169**:443.
5. Haudenschild, D. *et al.* (2002) *J. Biol. Chem.* **277**:4309.